The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
璐璐
invisight
DW
v0id
林狗
aaaa
xing_xing
牧青
极限001
123
wangyumumu
pluto
渡人舟
OK
aajhajkahna
学术文献互助
wch666
谢雷XIELei
zd
乐空思
皖公网安备34019202002308
